METis TechBio key facts
- Developer of an artificial intelligence platform designed to optimize pharmaceutical formulation processes.
- It has raised $314.7M; the latest was IPO in Mar 2026.
- Notable investors include HSG (Hong Kong), CICC Capital, Beijing State-owned Capital Operation and Management, 5Y Capital, Source Code Capital — 19 tracked in total.
- Status: In IPO Registration.
Who backs METis TechBio
19+- ·The complete investor list: 19 names
- ·Watch METis TechBio: the Monday email on marks, rounds and moves
METis TechBio funding rounds
No funding rounds for METis TechBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
METis TechBio investors
19 investors are on record for METis TechBio, including HSG (Hong Kong), CICC Capital, Beijing State-owned Capital Operation and Management and 5Y Capital.
About METis TechBio
Developer of an artificial intelligence platform designed to optimize pharmaceutical formulation processes. The company offers software that helps pharmaceutical companies accelerate the movement of new drugs in the pipeline by optimizing pre-clinical trial operations, enabling users to efficiently conduct research and design.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2020
- Website
- metistechbio.com/
- Ownership
- In IPO Registration
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
METis TechBio doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.